



THE UNIVERSITY OF CHICAGO

ANNUAL UPDATES FROM **ASH 2023**

PRACTICE CHANGING ABSTRACTS

SAVE THE DATE

FRIDAY, MARCH 1, 2024

HYBRID FORMAT: VIRTUAL + LIMITED IN-PERSON ATTENDANCE
CONVENE | 333 NORTH GREEN STREET | CHICAGO, IL

COURSE DIRECTOR

Michael Bishop, MD | University of Chicago Medicine

TARGET AUDIENCE: This activity is designed for primary care physicians, hematologists, pathologists, medical oncologists, trainees, nurse practitioners, physician assistants, nurses, pharmacists, and other healthcare professionals dedicated to treating hematologic cancers.

- + This activity's goal is to join community-based providers and academic oncologists to improve the care and outcomes of patients with hematologic malignancies. To reach this goal, this activity will address early treatment options and medical advances that can be implemented to reduce cancer-related deaths, including CAR T-cell therapy and novel therapeutics for the state-of-the-art management of newly-diagnosed and relapsed blood cancers. It will keep all healthcare professionals who care for patients with hematologic malignancies abreast of the latest scientific updates, innovative ideas, and the timeliest issues related to their care.
- + It will also provide participants with information to improve patient management and care strategies. They will discuss rapidly evolving developments, discover new treatments for patients, and improve practice paradigms. This activity will educate them on best practices for treating hematologic cancers and inform them of the indications to refer patients for expert quaternary-level care for advanced cellular therapies.



AT THE FOREFRONT
**UChicago
Medicine**

LEARN MORE HERE:
www.ChicagoPostASH.com
CONTINUING EDUCATION ACCREDITATION BY UNIVERSITY OF CHICAGO